Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 tri…

M Buti, H Wedemeyer, S Aleman, V Chulanov, V Morozov, O Sagalova, T Stepanova, R G Gish, A Lloyd, K Deterding, D Manuilov, A H Lau, A O Osinusi, M Rock, C Kim, S Pandey, B Singh, P Lampertico · Zeitschrift für Gastroenterologie · 2025 · Heft 08 · S. e556